Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. develops enzyme-based solutions for therapeutics manufacturing, using its CodeEvolver technology to discover and improve high-performance enzymes. Company news commonly covers financial results, guidance, cash-runway commentary, and business updates tied to small molecule pharmaceutical biocatalysis, nucleic acid synthesis, and the ECO Synthesis manufacturing platform for enzymatic RNAi and siRNA production.
Recurring developments include partner and evaluation agreements, technology-transfer activity, quality-system and manufacturing-suite updates, conference data on ECO Synthesis capabilities such as phosphorothioate stereochemistry and ligation efficiency, and portfolio updates for enzymes used in branded pharmaceutical products.
Codexis (NASDAQ: CDXS) will participate in the Cantor Global Healthcare Conference 2026, held September 9-11, 2026, in New York. Management is scheduled for a fireside chat on Thursday, September 10, 2026, at 9:45 a.m. ET, with a live webcast and 90-day replay via Codexis’ investor relations website.
Codexis (NASDAQ: CDXS) reported second quarter 2026 revenue of $14.9 million, slightly below $15.3 million a year ago, as lower research and development revenue offset strong product growth. Product revenue rose to $13.2 million, with product gross margin improving to 73% from 72%.
Net loss narrowed to $12.0 million, or $0.13 per share, from $13.3 million, or $0.16 per share, driven by reduced R&D and SG&A expenses. As of June 30, 2026, Codexis held $54.9 million in cash, cash equivalents and short-term investments; a July equity raise added approximately $25 million in net proceeds, for pro forma cash of about $80 million.
The company reiterated 2026 guidance for total revenue of $72–$76 million and gross margin in the high-60% range, and expects its cash resources to fund planned operations, including build-out of its ECO GMP Manufacturing Center, through the end of 2028.
Codexis (Nasdaq: CDXS) announced the appointment of David Butler, PhD, to its Strategic Advisory Board, effective August 3, 2026. According to Codexis, Dr. Butler will provide technical guidance, industry expertise and strategic insight to support growth and innovation in complex oligonucleotide therapeutics manufacturing.
Dr. Butler brings over 20 years of oligonucleotide experience, including serving as Chief Technology Officer at Hongene Biotech from 2023 to 2026 and leadership roles at Wave Life Sciences, Korro Bio, Alltrna and Alnylam. Codexis also said that Carole Cobb will step down from the Strategic Advisory Board.
Codexis (NASDAQ: CDXS) announced it will report Q2 2026 financial results on Tuesday, August 11, 2026, after the market close. Management will host a conference call and webcast at 4:30 p.m. Eastern Time to review results and provide a business update.
Investors can access the live webcast via the Codexis Investor Relations website, with an archive available for 90 days. The live call is available at 877-705-2976 (domestic) or 201-689-8798 (international). A 48-hour telephone replay will be offered at 877-660-6853 (domestic) or 201-612-7415 (international), access ID 13726635.
Codexis (Nasdaq: CDXS) priced an underwritten public offering of 16,666,667 common shares at $1.50 per share, with expected net proceeds of approximately $23.1 million after underwriting discounts, commissions and estimated expenses. The transaction is expected to close on or about July 27, 2026, subject to customary conditions.
According to Codexis, underwriters have a 30-day option to buy up to an additional 2,500,000 shares at the same public price, less underwriting discounts and commissions. The company plans to use proceeds for working capital and other general corporate purposes, including research, development and business activities.
Codexis (Nasdaq: CDXS) has commenced an underwritten public offering of its common stock, with all shares to be sold by the company. Codexis also expects to grant underwriters a 30-day option to purchase up to an additional 15% of the offered shares on the same terms.
The size and terms of the offering remain subject to market and other conditions, and completion is not assured. According to Codexis, net proceeds are intended for working capital and general corporate purposes, including research, development and business activities. Piper Sandler and Cantor are joint bookrunning managers, with Craig-Hallum as co-manager. The offering uses an SEC registration statement declared effective on May 14, 2024 and will be made via prospectus and prospectus supplement.
Codexis (NASDAQ:CDXS) showcased advances in RNA therapeutic manufacturing at TIDES USA 2026, highlighting its ECO Synthesis platform for siRNA production with precise phosphorothioate stereochemistry control. Stereochemical control is described as increasingly important for potency, product quality, and potential new dosage forms.
The company also reported the ability to start enzymatic RNA synthesis from a single nucleotide, removing the need for starter oligonucleotides, and shared sustainability data showing over 50% lower global warming potential and about 2.7-fold lower impact on an input materials basis versus conventional methods.
Codexis (NASDAQ: CDXS) reported Q1 2026 revenue of $15.2 million and reiterated full‑year guidance of $72–$76 million. Product gross margin was 71%; net loss narrowed to $8.7 million ($0.10/share). Cash and short‑term investments totaled $65.1 million, which the company says funds operations through end of 2027.
The company highlighted ECO Synthesis® platform progress, three upcoming TIDES presentations on siRNA stereochemistry and ligation, a 50g siRNA supply agreement for pre‑IND studies, ISO 9001 certification, and plans for an ECO GMP Manufacturing Center.
Codexis (NASDAQ: CDXS) will present RNA manufacturing advances at TIDES USA, May 11–14 in Boston. Presentations cover ECO Synthesis® platform results on phosphorothioate stereochemistry control, ligation efficiency, process performance, and sustainability. Codexis will host a panel and maintain a booth (821) during the conference.
Codexis (NASDAQ: CDXS) will report Q1 2026 financial results on May 7, 2026 after market close. Management will host a conference call and webcast at 4:30 PM ET to discuss results and provide a business update. The live webcast will be archived for 90 days; telephone replay available for 48 hours (Access ID #13726635).